Cargando...
Lapatinib – Member of a New Generation of ErbB-Targeting Drugs
SUMMARY: Women with advanced or metastatic ErbB2 (HER2)-positive breast cancer have limited therapeutic options once their disease has progressed on trastuzumab-based standard initial chemotherapy regimens. Therefore, there has been a clear need for alternative treatments in this advanced setting. T...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
S. Karger GmbH
2010
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2931094/ https://ncbi.nlm.nih.gov/pubmed/20847830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000285750 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|